AHA Registry Analysis Links Cardiology Team Access to Anticoagulation Gaps

This is an observational registry analysis, not a clinical practice guideline, identifying institutional and patient social determinants that predict failure to prescribe guideline-directed oral anticoagulation in atrial fibrillation.

observationalregistry-analysisanticoagulationatrial-fibrillationsocial-determinantshealth-disparitiesmachine-learning Cardiology / Anticoagulation

Background Information

Social factors affect anticoagulant prescriptions for atrial fibrillation.

Understanding social determinants of health (SDOH) can improve the prescription of oral anticoagulants (OAC) for patients with atrial fibrillation, potentially reducing stroke risk. Out of 68,628 eligible patients, 1,345 (2.0%) did not receive guideline-directed OAC. The absence of a cardiology team had the highest impact with an adjusted odds ratio of 3.72. The study highlights key SDOH affecting OAC prescriptions, emphasizing the need for addressing institutional barriers like the absence of a cardiology team. Social determinants significantly influence OAC prescription practices for atrial fibrillation, with institutional factors playing a critical role.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Osawa I, Shimada YJ

Citation: Osawa I, Shimada YJ Social Determinants of Guideline-Directed Oral Anticoagulation Prescription in Patients With Atrial Fibrillation Without Contraindications: Findings From the American Heart Association Get With the Guidelines-Atrial Fibrillation Registry. Journal of the American Heart Association. 2026:e050448. doi:10.1161/JAHA.126.050448

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →